Day One Biopharmaceuticals is a clinical-stage biotechnology company focused on developing therapies for patients with cancer. The company's lead product candidate, DAY101, is a potent and selective oral inhibitor of FGFR3, a driver of bladder cancer. Day One is also developing a pipeline of other oncology drug candidates, including DAY102, a selective oral inhibitor of FGFR2b, and DAY301, a selective oral inhibitor of SHP2. The company is headquartered in South San Francisco, California.
Highest paying job titles at Day One Biopharmaceuticals include Director, Business Development, Director, Research, and Pharmacy Director